REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
3. Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis. 2020;7:308-19.
4. Luo YD, Yu HQ, Liu XY, et al. Prognostic and predicted significance of Ubqln2 in patients with hepatocellular carcinoma. Cancer Med. 2020;9:4083-94.
5. Feng R, Li J, Xuan W, Liu H, Cheng D, Wang G. An autophagy-related gene-based prognostic risk signature for hepatocellular carcinoma: construction and validation. Comput Math Methods Med. 2021;2021:5770228.
6. Li X, Xu W, Kang W, et al. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics. 2018;8:1740-51.
7. Liang JY, Wang DS, Lin HC, et al. A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. Int J Biol Sci. 2020;16:2430-41.
8. Ouyang G, Yi B, Pan G, Chen X. A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma. Cancer Cell Int. 2020;20:207.
9. Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-907.
10. Yang W, Niu L, Zhao X, et al. Development and validation of a survival model based on autophagy-associated genes for predicting prognosis of hepatocellular carcinoma. Am J Transl Res. 2020;12:6705-22.
11. Yang Y, Yao JH, Du QY, et al. Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT. Cancer Manag Res. 2019;11:5133-46.
12. Zhu Y, Wang R, Chen W, Chen Q, Zhou J. Construction of a prognosis-predicting model based on autophagy-related genes for hepatocellular carcinoma (HCC) patients. Aging. 2020;12:14582-92.
13. Liang TT, Shao Q, Deng ZC, Wang T, Kang QZ. Systemic expression analysis reveals prognostic significance of WIPI3 in hepatocellular carcinoma. Front Genet. 2020;11:847.
14. Liu L, Liao JZ, He XX, Li PY. The role of autophagy in hepatocellular carcinoma: friend or foe. Oncotarget. 2017;8:57707-22.
15. Huang F, Wang BR, Wang YG. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. World J Gastroenterol. 2018;24:4643-51.
16. Fang Q, Chen H. Development of a novel autophagy-related prognostic signature and nomogram for hepatocellular carcinoma. Front Oncol. 2020;10:591356.
17. Xu W, Guo W, Lu P, Ma D, Liu L, Yu F. Identification of an autophagy-related gene signature predicting overall survival for hepatocellular carcinoma. Biosci Rep. 2021;41:BSR20203231.
18. Fang S, Su J, Liang B, et al. Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells. Sci Rep. 2017;7:44039.
19. Xiong X, Wu M, Zhang H, et al. Atg5 siRNA inhibits autophagy and enhances norcantharidin-induced apoptosis in hepatocellular carcinoma. Int J Oncol. 2015;47:1321-8.
20. Ni HM, Woolbright BL, Williams J, et al. Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J Hepatol. 2014;61:617-25.
21. Pan J, Lu C, Jun W, et al. The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells. Int J Clin Exp Pathol. 2019;12:2622-30.
22. Gu Y, Li P, Peng F, et al. Autophagy-related prognostic signature for breast cancer. Mol Carcinog. 2016;55:292-9.
23. Ko YH, Cho YS, Won HS, et al. Prognostic significance of autophagy-related protein expression in resected pancreatic ductal adenocarcinoma. Pancreas. 2013;42:829-35.
24. Zhang H, Lu X, Wang N, et al. Autophagy-related gene expression is an independent prognostic indicator of glioma. Oncotarget. 2017;8:60987-1000.
25. Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
26. Wang Z, Jensen MA, Zenklusen JC. A practical guide to the cancer genome atlas (TCGA). In: Mathé E, Davis S, Editors. Statistical genomics. New York: Springer; 2016. pp. 111-41.
27. Li C, Wu ZH, Yuan K. Autophagy-related signature for head and neck squamous cell carcinoma. Dis Markers. 2020;2020:8899337.
28. Zhang J, Zhang M, Huang J, et al. Development and validation of an autophagy-related gene signature for predicting the prognosis of hepatocellular carcinoma. Biomed Res Int. 2021;2021:7771037.
29. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape stringApp: network analysis and visualization of proteomics data. J Proteome Res. 2019;18:623-32.
30. Xu YY, Zhou H, Murphy RF, Shen HB. Consistency and variation of protein subcellular location annotations. Proteins. 2021;89:242-50.
31. Lin S, Zheng L, Lu Y, Xia Q, Zhou P, Liu Z. Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma. Cancer Med. 2020;9:8624-38.
32. Lv J, Zhu Y, Ji A, Zhang Q, Liao G. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer. Biosci Rep. 2020;40:BSR20194337.
33. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217-21.
34. Hu J, Qiu D, Yu A, et al. YTHDF1 is a potential pan-cancer biomarker for prognosis and immunotherapy. Front Oncol. 2021;11:607224.
35. Liu J, Chen Z, Zhao P, Li W. Prognostic and immune regulating roles of YIF1B in Pan-cancer: a potential target for both survival and therapy response evaluation. Biosci Rep. 2020;40:BSR20201384.
36. Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509-14.
37. Zhang Z, Zhang Y, Mo W. The autophagy related gene CHAF1B is a relevant prognostic and diagnostic biomarker in hepatocellular carcinoma. Front Oncol. 2020;10:626175.
38. Lin Z, Niu Y, Wan A, et al. RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39:e103181.
39. Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the mammalian target of rapamycin pathway in liver cancer: from molecular genetics to targeted therapies. Hepatology. 2021;73:49-61.
40. Wei Q, Zhu R, Zhu J, Zhao R, Li M. E2-induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells. Oncol Res. 2019;27:827-34.
41. Huo X, Qi J, Huang K, et al. Identification of an autophagy-related gene signature that can improve prognosis of hepatocellular carcinoma patients. BMC Cancer. 2020;20:771.
42. Fan Q, Yang L, Zhang X, et al. Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/β-catenin signaling pathway activation in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2018;37:9.
43. Li J, Yang B, Zhou Q, et al. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis. 2013;34:1343-51.
44. Deng G, Zeng S, Qu Y, et al. BMP4 promotes hepatocellular carcinoma proliferation by autophagy activation through JNK1-mediated Bcl-2 phosphorylation. J Exp Clin Cancer Res. 2018;37:156.
45. Song Z, Zhang G, Yu Y, Li S. A prognostic autophagy-related gene pair signature and small-molecule drugs for hepatocellular carcinoma. Front Genet. 2021;12:689801.
46. Wei Y, Chen X, Liang C, et al. A noncoding regulatory RNAs network driven by Circ-CDYL acts specifically in the early stages hepatocellular carcinoma. Hepatology. 2020;71:130-47.
47. Roca H, Varsos Z, Pienta KJ. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem. 2008;283:25057-73.
48. Peng Y, Liu C, Li M, et al. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. Cancer Cell Int. 2021;21:98.
49. Liu F, Sun Y, Liu B, et al. Insulin-like growth factor-1 induces epithelial-mesenchymal transition in hepatocellular carcinoma by activating survivin. Oncol Rep. 2018;40:952-8.
51. Cao L, Li C, Shen S, et al. OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma. BMC Cancer. 2013;13:82.
52. Xu M, Hu X, Zhang M, Ge Y. What is the impact of BIRC5 gene polymorphisms on urinary cancer susceptibility? Gene. 2020;733:144268.
53. Fernández JG, Rodríguez DA, Valenzuela M, et al. Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription. Mol Cancer. 2014;13:209.
54. Cao D, Chen MK, Zhang QF, et al. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes. Aging. 2020;12:12187-205.
55. Dong LY, Zhou WZ, Ni JW, et al. Identifying the optimal gene and gene set in hepatocellular carcinoma based on differential expression and differential co-expression algorithm. Oncol Rep. 2017;37:1066-74.
56. Xiao H, Wang B, Xiong HX, et al. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. J Cell Physiol. 2021;236:2572-91.
57. Domingues P, González-Tablas M, Otero Á, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun. 2016;53:1-15.
58. Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169:1342-56.e16.
59. Sun H, Liu L, Huang Q, et al. Accumulation of tumor-infiltrating CD49a+ NK cells correlates with poor prognosis for human hepatocellular carcinoma. Cancer Immunol Res. 2019;7:1535-46.
60. Pourbagheri-Sigaroodi A, Fallah F, Bashash D, Karimi A. Unleashing the potential of gene signatures as prognostic and predictive tools: a step closer to personalized medicine in hepatocellular carcinoma (HCC). Cell Biochem Funct. 2024;42:e3913.
61. Zhou Y, Shan R, Xie W, et al. Role of autophagy-related genes in liver cancer prognosis. Genomics. 2024;116:110852.
62. Zhang H, Xia P, Liu J, Chen Z, Ma W, Yuan Y. ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival. Int J Biol Sci. 2021;17:4442-58.
